#POLB Poolbeg Pharma – Notice of Results

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model , will announce its results for the period ended 31 December 2021 on Thursday 3 March 2022. The Company will be hosting an online presentation for investors on the same day, at 6:00pm GMT on the Investor […]

#POLB Poolbeg Pharma – Artificial Intelligence deal with OneThree Biotech

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an agreement with OneThree Biotech, Inc . a biology-driven artificial intelligence (‘AI’) company, to identify new drug targets and treatments for Respiratory Syncytial Virus (‘RSV’).   Under the terms of the transaction and as aligned with […]

Poolbeg Pharma #POLB – Article – Further Assets

Artificial Intelligence gives unique insight to #drug discovery by spotting links that humans miss. These links identify new #drugs likely to succeed in clinic. In a crowded industry, #AI gives #POLB the edge Learn more: https://poolbegpharma.com/pipeline/further-assets/…

Poolbeg Pharma #POLB – Upcoming London Webinar

  CEO of Poolbeg Pharma, will be presenting at next weeks London South East webinar. They look forward to providing updates on recent Company news. Register to attend: https://us02web.zoom.us/webinar/register/1716431929653/WN_ZJVzMqdWTgWYBetrouIuFg  

#POLB Poolbeg Pharma – Confirmation of vaccine platform licence execution

31 January, 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, confirms that it has signed the licence to AnaBio Technologies’ (‘AnaBio’) microencapsulation and nanoencapsulation technologies to develop an oral vaccine delivery platform. This follows the binding term sheet announced on […]